Stockreport

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine [Read more]